Core Insights - Lenskart Solutions Ltd., backed by SoftBank Group Corp., raised 72.8 billion rupees ($821 million) in its IPO, leading to discussions about high valuations in the Indian startup ecosystem [1][2] - The stock experienced volatility on its debut, initially dropping by 12% before closing up 0.3% [1] - The IPO was oversubscribed by 28 times, primarily driven by institutional investors, but the valuation at 238 times last fiscal year's earnings raised concerns [2][3] Company Performance - Lenskart's shares fluctuated significantly on the first trading day, indicating market uncertainty regarding its valuation [1] - The company's market value post-IPO is approximately 700 billion rupees, surpassing established consumer brands like Colgate-Palmolive India Ltd. and United Breweries Ltd. [4] Market Context - The IPO reflects India's growing status as a global fundraising hub, with nearly $17 billion raised in 2025 from Indian debuts [3] - Upcoming IPOs in India include Billionbrains Garage Ventures Ltd. and Pine Labs Ltd., indicating continued investor interest in the market [4] Investor Sentiment - Despite the strong business fundamentals, some analysts, including Ambit Capital, have issued sell recommendations due to high valuations [2][3] - DSP Asset Managers publicly defended its investment in Lenskart, acknowledging the company's scalability while recognizing the deal's expense [3][5]

Group 1: WeWork IPO - WeWork India's IPO has seen a muted demand with only 13% subscription on the second day [1] - The IPO is priced between ₹615 and ₹648 per share and is entirely an offer for sale, with no proceeds going to the company [1] - Anchor investors have committed ₹1,348 crore ahead of the IPO, but brokerages express caution due to high valuations and fixed costs despite the strong brand and profitability [1] Group 2: Eli Lilly Investment - Eli Lilly and Company plans to invest over $1 billion in a new contract manufacturing facility in Hyderabad, India [2] - The new hub will enhance Lilly's manufacturing network with advanced technical and quality capabilities, and hiring has already begun [2] - This investment reflects Lilly's global expansion strategy and confidence in India's talent and infrastructure, with over $55 billion committed to global facilities since 2020 [2] Group 3: Cough Syrup Investigation - A Special Investigation Team (SIT) has been formed to investigate the deaths of 14 children in Chhindwara, linked to a toxic cough syrup [3] - The cough syrup, manufactured in Tamil Nadu, has been banned by the state, and a wider investigation is underway [3] - The syrup was found to contain diethylene glycol, prompting nationwide scrutiny of similar drugs [3]